Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), has successfully completed a Good Manufacturing Practice (GMP) inspection conducted by the Brazilian regulatory authority, ANVISA.
In the exchange filing, the company shared, 'This is to inform you that the Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. '
The inspection took place from June 30 to July 4, 2025, and concluded with no critical or major observations—a key milestone for the company's global regulatory compliance. Only minor procedural observations and recommendations were noted, which were discussed during the course of the audit.
Shilpa Medicare stated that it remains committed to maintaining the highest quality and regulatory standards. The company will submit a Corrective and Preventive Action (CAPA) plan to address the minor points raised, within the stipulated timelines set by the agency.
This successful outcome reinforces Shilpa's position in regulated markets and supports its ongoing efforts to expand its international presence, particularly in Latin America.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
30 minutes ago
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. 'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage. Doctors say the situation forces them to get creative in treating patients, but there's hope that prices may fall more in the future. Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity. Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers. Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales. The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members. And Novo says 85% of its patients who have coverage in the U.S. pay $25 or less per month. Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition. But most state and federally funded Medicaid programs don't cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older. Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang. Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited. 'Coverage is not the same as access,' said Tchang, a New York-based doctor who serves as a paid advisor to both Novo and Lilly. Bill-payers like employers are nervous about drugs that might be used by a lot of people indefinitely. Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers. One of the nation's largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy. That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous. Dr. Courtney Younglove's office sends prospective patients a video link showing them how to check their insurer's website for coverage of the drugs before they visit. 'Then some of them just cancel their appointment because they don't have coverage,' the Overland Park, Kansas, doctor said. Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs. But the U.S. Food and Drug Administration determined earlier this year that the shortage had ended. That should have ended the compounded versions, but there is an exception: Some compounding is permitted when a drug is personalized for the patient. The health care company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects. Hims says these plans start at $165 a month for 12 months, with customers paying in full upfront. It's a contentious issue. Eli Lilly has sued pharmacies and telehealth companies trying to stop them from selling compounded versions of its products. Novo recently ended a short-lived partnership with Hims to sell Wegovy because the telehealth company continued compounding. Novo says the compounded versions of its drug put patient safety at risk because ingredients are made by foreign suppliers not monitored by US regulators. Hims says it checks all ingredients to make sure they meet U.S. quality and safety standards. It also uses a third-party lab to verify that a drug's strength is accurately labeled. Both drugmakers are selling most of their doses for around $500 a month to people without insurance, a few hundred dollars less than some initial prices. Even so, that expense would eat up about 14% of the average annual per person income in the U.S., which is around $43,000. There are some factors that may suppress prices over time. Both companies are developing pill versions of their treatments. Those could hit the market in the next year or so, which might drive down prices for the older, injectable doses. Younglove said some of her patients save as much as 15% by getting their doses shipped from a pharmacy in Canada. They used to get them from an Israeli pharmacy until the Canadians dropped their prices. She says competition like this, plus the introduction of pill versions, will pressure U.S. prices. 'I think price wars are going to drive it down,' she said. 'I think we are in the early stages. I have hope.'
Business Upturn
34 minutes ago
- Business Upturn
ACME Solar places over 3.1 GWh of Battery Energy Storage System orders
ACME Solar has recently informed exchanges that the company placed a major order for over 3.1 GWh of Battery Energy Storage Systems (BESS), making it one of the largest such procurements in India to date. The order has been placed with top global energy storage suppliers, including Zhejiang Narada and Trina Energy, both known for their high-efficiency and scalable solutions. The storage systems will support ACME Solar's upcoming renewable energy projects, including Firm & Dispatchable Renewable Energy (FDRE) initiatives and battery-linked plants, scheduled for rollout across multiple Indian states over the next 12 to 18 months. Deliveries will happen in phases over the next four to eight months of the current financial year. ACME noted that the order fits well within its planned budget, helping maintain capital efficiency while focusing on strong technical performance and reliable supply. The early procurement move is also expected to speed up project execution and ensure faster revenue realization. The BESS equipment meets international safety and quality standards like IEC and UL, adding to the overall reliability of the infrastructure. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
35 minutes ago
- Business Upturn
HCLSoftware launches Domino 14.5 with focus on data privacy
By Aman Shukla Published on July 7, 2025, 12:27 IST HCLSoftware has rolled out version 14.5 of its HCL Domino platform, with a focus on meeting the needs of governments and other organizations that handle sensitive data. This update introduces several changes aimed at improving data privacy, security, and compliance, particularly in regions with strict regulations. A key part of this release is Domino IQ, a new AI extension designed to give users more control over how artificial intelligence is applied within their systems. Instead of relying on external or cloud-based AI services, organizations can use their own models or ones developed by trusted partners. This approach not only helps in meeting local compliance requirements, such as those outlined in the European AI Act, but also reduces dependence on non-domestic infrastructure. In addition to AI tools, the new version includes updates to improve security and accessibility. The platform now supports tools for managing security events and incidents, and has received certification aligned with BSI standards. It also meets the guidelines laid out in the European Accessibility Act, ensuring that its web-based services are more usable for a wider range of business users. The update also brings improved deployment options for secure messaging and virtual meetings. Overall, HCL Domino 14.5 appears to be tailored for organizations operating under strict regulatory conditions, offering a platform that's designed to keep data handling and collaboration both compliant and contained within trusted environments. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
